FBLG
HEALTHCAREFibroBiologics Inc
$1.29-0.04 (-3.01%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving FBLG Today?
No stock-specific AI insight has been generated for FBLG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.03$22.60
$1.29
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-7.02
Dividend Yield—
Dividend / Share—
ROE-4.2%
Profit Margin—
Debt / Equity—
Trading
Volume196K
Avg Volume (10D)—
Shares Outstanding5.2M
FBLG News
21 articles- FibroBiologics CEO Issues Letter to ShareholdersYahoo Finance·May 5, 2026
- FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce ScarringYahoo Finance·May 4, 2026
- FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialYahoo Finance·May 4, 2026
- FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate UpdateYahoo Finance·Apr 30, 2026
- FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026Yahoo Finance·Apr 30, 2026
- FibroBiologics Compliant with All Nasdaq Listing RequirementsYahoo Finance·Apr 20, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and ImmunityYahoo Finance·Apr 10, 2026
- FibroBiologics Announces Closing of $3 Million Public OfferingYahoo Finance·Apr 2, 2026
- FBLG: Advancing Fibroblast Therapy on Multiple FrontsYahoo Finance·Apr 1, 2026
- FibroBiologics Announces Pricing of $3 Million Public OfferingGlobeNewswire Inc.·Apr 1, 2026
- FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical TrialYahoo Finance·Mar 31, 2026
- FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price RequirementYahoo Finance·Mar 25, 2026
- FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid TechnologyYahoo Finance·Mar 12, 2026
- FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot UlcersYahoo Finance·Mar 5, 2026
- FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of OsteoporosisYahoo Finance·Mar 2, 2026
- FBLG: Ready to Transition to Clinical-Stage CompanyYahoo Finance·Feb 27, 2026
- FibroBiologics to Present at the BIO Investment & Growth SummitYahoo Finance·Feb 26, 2026
- FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 24, 2026
- FibroBiologics Granted Extension by Nasdaq to Regain ComplianceYahoo Finance·Feb 23, 2026
- FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown UniversityYahoo Finance·Feb 10, 2026
All 21 articles loaded
Price Data
Open$1.28
Previous Close$1.33
Day High$1.32
Day Low$1.22
52 Week High$22.60
52 Week Low$1.03
52-Week Range
$1.03$22.60
$1.29
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-7.02
Dividend Yield—
Dividend / Share—
ROE-4.2%
Profit Margin—
Debt / Equity—
Trading
Volume196K
Avg Volume (10D)—
Shares Outstanding5.2M
About FibroBiologics Inc
FibroBiologics, Inc. is a leading biotechnology company at the forefront of regenerative medicine, specializing in the innovative application of fibroblast cells to address degenerative diseases and spinal disorders. With a solid intellectual property portfolio, the company is well-positioned in the competitive cellular therapy market, emphasizing clinical innovation and excellence. Through strategic collaborations and active research efforts, FibroBiologics is committed to revolutionizing healthcare and improving patient outcomes with its groundbreaking therapeutic products.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—